Boston Scientific (BSX) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Boston Scientific reported revenue of $4.66 billion for the quarter ended March 2025, reflecting a year-over-year increase of 20.9% and surpassing the Zacks Consensus Estimate of $4.56 billion by 2.31% [1] - The company's EPS for the quarter was $0.75, an increase from $0.56 in the same quarter last year, exceeding the consensus EPS estimate of $0.67 by 11.94% [1] Financial Performance - Geographic Revenue from the U.S. was $2.96 billion, exceeding the average estimate of $2.86 billion and showing a year-over-year growth of 31.1% [4] - Revenue from the Rest of the World was reported at $1.70 billion, matching the average estimate from analysts [4] - Net Sales in Cardiovascular- Worldwide reached $3.09 billion, surpassing the average estimate of $2.96 billion and representing a 26.2% year-over-year increase [4] - Net Sales in MedSurg- Worldwide totaled $1.58 billion, slightly below the average estimate of $1.59 billion, but still reflecting an 11.7% increase compared to the previous year [4] Segment Performance - Cardiovascular- Cardiology- Worldwide sales were $2.43 billion, exceeding the estimated $2.31 billion and showing a 29.8% year-over-year growth [4] - MedSurg- Neuromodulation- Worldwide reported sales of $271 million, above the average estimate of $266.87 million, with a year-over-year increase of 5.9% [4] - Cardiovascular- Peripheral Interventions- Worldwide sales were $656 million, slightly below the average estimate of $658.51 million, but still reflecting a 14.5% year-over-year increase [4] Stock Performance - Over the past month, Boston Scientific shares have returned -7.8%, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]